Cathie Wood-led Ark Investment Management on Thursday bought 162,276 shares of Schrodinger Inc (NASDAQ: SDGR) through the Ark Genomic Revolution ETF (BATS: ARKG), trading disclosure by the firm showed. The purchase is valued at over $4.6 million based on Thursday's closing price.
Schrodinger is the ninth largest holding in the ARK Genomic Revolution ETF valued at over $104 million with a weight of 3.78%. The company provides software platform for drug and materials discovery and counts Microsoft Inc. (NASDAQ: NASDAQ:MSFT) co-founder Bill Gates' among long-term backers.
The company reported in early August second-quarter revenue of $38.5 million compared with $29.8 million in the same period last year. It guided to a full-year revenue to $161 million-$181 million, representing 17-31% percent growth.
Schrodinger recently appointed Geoffrey Porges as its chief financial officer.
Also Read: Alibaba (NYSE:BABA), Other Hong Kong Stocks Show Optimism In Early Trade Even As Analysts Downgrade China Growth Projections
Cathie Wood also bought over 1 million shares of biotech firm Ginkgo Bioworks Holdings Inc (NYSE: DNA), valued at over $3.7 million, through two of Ark’s ETFs.
Ginkgo Bioworks is the 17th largest holding in the firm’s flagship ARK Innovation ETF (NYSEARCA: ARKK) with a weight of 2.39%.
Key Disposals: Wood sold 313,211 shares of Signify Health Inc (NYSE: SGFY), via two of the firm’s ETFs, valued at over $6.8 million based on Thursday’s closing price.
Wood sold Twitter Inc . (NYSE: NYSE:TWTR) shares yet again on Thursday, selling 50 shares valued at $2,193.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read at Benzinga